Syndax Pharmaceuticals Inc (SNDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $850.77M
Last updated: Nov 17, 2026 at 4:15 PM ET
Syndax Pharmaceuticals Inc (SNDX) Stock Chart
Syndax Pharmaceuticals (SNDX) has a latest price of $9.20 on Nov 17, 2026, 64.0% below its 52-week high of $25.59. Its price fell 44.6% over the past 12 months. The month-end price rose 15.6% over the 10 years through Oct 2026, a compound annual rate of 1.5%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $28.70 in Jan 2023 and its lowest $4.45 in Dec 2018, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart SNDX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for SNDX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 55.7%, and over 6 months it fell 52.5%. The month-end price fell 3.1% over the 3 years through Oct 2026, a compound annual decline of 1.0%.
| Period | Change |
|---|---|
| 1 month | -29.7% |
| 3 months | -55.7% |
| 6 months | -52.5% |
| 12 months | -44.6% |
| 12 months, with dividends | -44.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -3.1% | -1.0% |
| 5 years | -29.8% | -6.8% |
| 10 years | +15.6% | +1.5% |
Price by Year
Its best calendar year was 2020, when the price rose 153.3%, and its weakest was 2018, when it fell 49.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $13.65 | -35.0% |
| 2025 | $21.01 | +58.9% |
| 2024 | $13.22 | -38.8% |
| 2023 | $21.61 | -15.1% |
| 2022 | $25.45 | +16.3% |
| 2021 | $21.89 | -1.6% |
| 2020 | $22.24 | +153.3% |
| 2019 | $8.78 | +97.3% |
| 2018 | $4.45 | -49.2% |
| 2017 | $8.76 | +22.2% |
Trading Range
The price is 38.0% below its 50-day average of $14.83 and 53.1% below its 200-day average of $19.61.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $9.20 | |
| 52-week high | $25.59 | -64.0% |
| 52-week low | $9.06 | +1.5% |
| 50-day average | $14.83 | -38.0% |
| 200-day average | $19.61 | -53.1% |
Price Risk
Over 3 years, its largest fall from a peak was 64.8%.
| Measure | Value |
|---|---|
| 1-year beta | 0.78 |
| Largest fall, 1 year | -63.7% |
| Largest fall, 3 years | -64.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About SNDX
What is SNDX's 1-year price change?
Syndax Pharmaceuticals's price fell 44.6% over the past 12 months. With dividends included, the 12-month total return was -44.6%.
What is SNDX's 5-year price change?
Syndax Pharmaceuticals's month-end price fell 29.8% over the 5 years through Oct 2026, a compound annual decline of 6.8%. These figures leave out dividends.
What is SNDX's 52-week high and low?
Syndax Pharmaceuticals's 52-week high is $25.59 and its 52-week low is $9.06. Its latest price of $9.20 on Nov 17, 2026 is 64.0% below the high.
What is SNDX's beta?
Syndax Pharmaceuticals's 1-year beta against the S&P 500 is 0.78, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 63.7%.
Is the SNDX chart free?
Yes. Advanced Charting for SNDX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
SNDX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors